@TataConsumer
Brands
Tata salt largest salt brand in India
Tata tea 2nd largest tea brand in India
Tetley 4th largest tea brand in UK & largest in Canada
Himalayan 1st natural mineral water brand in India
Tata sampann Leading national brand
8'0 clock 4th in R&G coffee in US
9.6K crore consolidated revenue in FY20, current MKT cap 47K cr
Reach - 200 mn households in India,distribution 2.2 mn retail outlets
Among top 10 FMCG companies in India
2250 employees
Number 2 branded tea player globally
Aspiring to get a larger share of Fmcg mkt in India
Executive summary
Cons revenue grew 19% to 2781cr,strong growth India business
Cons Ebidta grew 26% ,INR 402 cr
Packaged beverage business India grew 29%
India food business grew 13%
Branded Int beverage business grew 11%
Cons PBT for the quarter higher ht 31% ,345 cr
#Nifty
@TataConsumer

Group performance at a glance
Revenue 2781 cr
Ebidta 402 cr
PBT 345 cr
Group net profit 273 cr
Net cash 1439 cr
Eps 2.79
Cash Eps 4.08

#TataConsumer
Regular black tea growth softened in US,Canada compared to Q1
Non black tea continued momentum in Int mkts
Post lifting lockdown Indian mkt swung from -6% in Apr-Jun to +6% in July-Sep in branded tea
US coffee both bags & K-cups continue to grow driven
#sensex #StockMarket
Key integration milestones
Integration to be completed substantially by Q4fy21
Synergy identification complete,benefit from Q3fy21
2 of 3 stages of distributor consolidation complete
Outlet reach expanded 12% till Sep20
Digitization across field force,ERP integration, automatn
India packaged beverages
+29% revenue growth
+12% volume growth
India foods
+13% revenue growth
+6% volume growth
Double digit growth in salt & tata Sampann
Salt revenue grew 10% in Q2
Pulses growth 35%

Nourish co
38 cr revenue
87% precovid levels
#TataConsumer
Tata coffee
+17% revenue growth
+6% plantations vol growth
+11% extraction vol growth
Tata coffee grew 17% led by Vietnam
Plantation business grew by 26% value term
Significant growth in pepper vols
Extraction business growth 13%
Vietnam plant operating at 90% capacity
#stock
Tata Starbucks
86% stores reopened,196 stores,12 cities
3 all women stores opened
Opened 11 new stores,1 new city Lucknow
MSR members 8.13 lakhs ,+20% YoY
Launched Mobile order & pay feature,pre order on Starbucks India app
Recognized as Indias top 100 companies for women
UK Mkt
Strong quarter for good earth, achieved 1% share of Sainsbury tea category
Tetley herbal tea range launched
4% revenue & 20.5% value mkt share growth
OOH & wholesale channel facing headwinds,also cold infusion category
#TataConsumer
#Nifty #sensex #UKlockdown
US Mkt
New good earth sensorial blends & Tetley British blends launched
+4% cpffee revenue & +5.4% bags coffee mkt share growth
Tea - revenue growth 11 & vol growth of 8%
Food business facing headwinds
Canada Mkt
New Tetley super tea immune booster & Herbal (cinnamon ,turmeric) launched
1% revenue & 29.5% mkt share growth
25% revenue growth in speciality tea
Tetley #1 in speciality tea
Vol decline of 7% driven by discontinuation of ethnic teas
Improved profitability
Financial highlights
Revenue growth 19%( india beverages 32%, india food 13%, Int business 11% excluding food ,tata coffee 17%)
Group ebidta growth 26%

Q2fy21/ Q2fy20 cr
Revenue 1736 /1427
Ebidta 254/205
PAT 169/155

1HFY21 / 1HFY20
Revenue 3342/2891
Ebidta 579/439
PAT 402/310
Segment performance
Q2fy21 / Q2fy20 cr
India beverages 1120/848
India foods 580/513
Int beverage 801/746
Total branded business 2501/2106
Non branded 288/242
Total 2781/2347

Revenue
+45% india beverages
+23% india foods
+32% International beverages

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with TheMarket🐝

TheMarket🐝 Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @BullsforBears

8 Nov
@MarksansPharma #marksanspharma Investor presentation Sep ' 20

Revenue growth 36.3%
Ebidta growth 109.5%
PAT growth 95.4%
Cash 154.4 crores
ROCE - Mar'18 12.1% ,Sep'20 29.4%
ROE - Mar'18 7.5% ,Sep 20 22.8%
Net debt to Ebidta - Mar'18 0.89 ,Sep 20 -0.48
Q2fy21 / Q2fy20 in cr
Revenue 360/264
Ebidta 86.8/41.4
Ebidta margin 24.1/15.7%
PAT 50.7/26
PAT margin 14.1/9.8%

H1fy21 /H1fy20
Revenue 691/511
Ebidta 157/76
Ebidta margin 22.7/14.9%
PAT 100/48.5
PAT margin 14.5/9.5%

#nifty #sensex #StockMarket #stocks #markets
95% of company revenues came from regulated overseas mkt

Formulation business from Europe,UK 286cr compared to 225cr last year,growth 27%
US & North America growth 48.7% to 302.5 cr in H1fy21
Australia & NZ revenue 69.4 cr in H1fy21 ,growth of 12.1% YOY
#pharma
Read 14 tweets
6 Nov
#sequentScientific
Q2Fy21 / Q2Fy20 (in million)
Revenue 3463 /2842 (growth 21.8%)
Ebidta 598/378 (growth 58.2%)
Ebidta margin 17.3/13.3 %

H1Fy21 /H1Fy20
Revenue 6565/5622(growth 16.8%)
Ebidta 1119 /763( growth 46.7%)
Ebidta margin 17/13.6%

#nifty #sensex #StockMarket #stocks
The making of Sequent 1
Focus - transition from multi business model to pure play animal health business
Scale - Indias largest & amongst worlds top 20 animal health company
Capabilities - across APIs & formulations
Financial - mid teen Ebidta margin,RoCe 20s,good cash flow
Carlyle acquired 25.2% ,became new promoter on Aug 17,2020 & acquired additional 27.82% on Sep 8 2020
Neeraj Bharadwaj ,Rahul Mukim & Gregory John Andrew's join board as Carlyle nominees

@OneCarlyle #sequentScientific
Read 13 tweets
6 Nov
#unitedspirits #diageoindia

Q2fy21
Net sales declined 6.6%,sequentially improved over last quarter
Net sales declined 3.4% after adjusting for one off benefit of bulk scotch sales last yr
Prestige & above segment grew 1%
Popular segment sales declined 12.5 over last yr
#nifty
Priority sales declined 10% over last year,increased consumer prices & unfavorable state mix impacted demand
Gross margin down 42.1% over 284bps driven by contraction in Andhra pradesh & decline in south franchise business
Ebidta 270cr ,down 35.1%,Ebidta margin 12.6% down
Ebidta margin affected by higher A&P investment to support rollout of 2 core brands, Mcdowells No.1 whiskey & Royal challenge
Interest cost 51 cr,12% higher compared to last year
PAT 128 cr, down 43%
#nifty #sensex #StockMarket #stocks @United_Spirits
Read 6 tweets
31 Oct
@SyngeneIntl conference call transcript Q2FY21

Revenue from operations up 12%, 519 cr ,Ebidta 169 cr, PAT 84 cr
#COVID19 impacting operations of the company & its clients
Set up the busiest PCR testing center in Bangalore
Overall growth driven by discovery science,R & D center
Significant success for 2 clients
1)Albireo pharma - compound Odevixibat met primary endpoint in phase 3 for children suffering genetic liver disease
Syngene worked on registration batches to phase 3,helping in
regulatory filings

#pharma #Nifty
2) C4 therapeutics - biopharmaceutical company, novel therapy for cancer & neurodegenerative disease through Targeted protein degradation, recognized leader ,syngene conducted discovery research projects for C4 over last 3 years
#sensex #cdmo
Read 11 tweets
29 Oct
#Navinfluorine investor presentation Q2fy21

Revenue 512 cr
High value business
H1FY20/H1FY21 - 253/332 ,increase 32%
Ebidta - 146 cr
Operating PBT - 125cr

H1FY21 revenue contribution from high value business - 65%

#Nifty #sensex #StockMarket #stocks
Q2FY21
Revenue 308 cr
High value business Q2Fy20/Q2Fy21- 141/201 ,increase 42%
Ebidta 93cr
PBT 83cr

H1Fy20/H1Fy21

Legacy business 253/180 ,decrease 29%

High value business
253/332 ,increase 32%

Total revenue 506/512 ,increase 1%

Operating Ebidta 128/146

#chemicals
Speciality chemicals well balanced growth driven by life sciences & crop science segments

CRAMS Strong customer traction augurs well

H1FY20/H1FY21

Speciality business
180/199 ,increase 11%
CRAMS 72/133, increase 84%
High value business units 253/332,increase 32%
#crams #cdmo
Read 6 tweets
29 Oct
Piramal Q2 results update
28% increase in equity
39% reduction in debt D/E 0.96
12% YoY increase net profit 1124cr
No.of exposure >15% net worth of financial services - 1
Pharma arm valued EV of $ 2.7-3.1bn
CDMO revenue growth YoY 20%
@PiramalGroup #pharma #Nifty #sensex
India consumer product YoY growth +25%
Ebidta margin Q2fy21 23%
Net debt :
Mar'19 - 55,122cr
Oct'20 - 33457 cr
D/E - 2 to 0.96
Segment wise equity allocation
Financial 48%
Pharma 22%
Unallocated 23%

Equity of 25,000 cr for financial services to acquire oppurtunities
Consolidation in real estate picking pace - industry wise decline in number of developers since 2012 - 53%

Wholesale loanbook
Mar 19 - 51436cr
Sep 20 - 45840cr

Top 10 exposure
Mar 19 - 18404cr
Sep 20 - 14717cr,down by 20%
No.of account with> 15% net worth decreased frm 3 to 1
Read 6 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!

Follow Us on Twitter!